Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative precision medicines for serious conditions of unmet medical need in oncology. The company is focused on advancing two main drug candidates, NXP800 and NXP900, with ongoing clinical trials and strategic collaborations aimed at improving cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Products
Oral small‑molecule GCN2 kinase activator (clinical candidate)
An orally bioavailable small molecule that activates the GCN2 kinase to induce an integrated stress response and reduce bulk protein synthesis, evaluated in preclinical models and early clinical trials for selected oncology indications.
Oral small‑molecule SRC family kinase inhibitor (clinical candidate)
An orally bioavailable small molecule designed to inhibit the SRC family kinases, including catalytic and scaffolding functions, developed for oncology indications and evaluated in early clinical dose‑escalation studies.
Oral small‑molecule GCN2 kinase activator (clinical candidate)
An orally bioavailable small molecule that activates the GCN2 kinase to induce an integrated stress response and reduce bulk protein synthesis, evaluated in preclinical models and early clinical trials for selected oncology indications.
Oral small‑molecule SRC family kinase inhibitor (clinical candidate)
An orally bioavailable small molecule designed to inhibit the SRC family kinases, including catalytic and scaffolding functions, developed for oncology indications and evaluated in early clinical dose‑escalation studies.
Services
Collaborative execution of investigator‑initiated and company‑sponsored early‑phase oncology trials with academic partners and clinical sites.
Design and execution of preclinical efficacy, mechanism‑of‑action and biomarker studies to support candidate selection and clinical translation.
Collaborative execution of investigator‑initiated and company‑sponsored early‑phase oncology trials with academic partners and clinical sites.
Design and execution of preclinical efficacy, mechanism‑of‑action and biomarker studies to support candidate selection and clinical translation.
Expertise Areas
- Early‑phase clinical development
- Precision oncology drug discovery
- Kinase‑targeted small‑molecule therapeutics
- Preclinical pharmacology and in vivo modeling
Key Technologies
- Small‑molecule kinase modulation
- Multi‑omics biomarker analysis
- Xenograft and PDX tumor models
- Cell‑based proliferation and signaling assays
News & Updates
Nuvectis Pharma announced that Ron Bentsur, Chairman and CEO, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
The company reported clinical data for NXP900, demonstrated robust pharmacodynamic response, and announced a $15.5M financing extending cash runway into Q1 2027.
Highlights from the company's research on NXP900, including its pharmacodynamic responses and safety profile.
Nuvectis Pharma announced that Ron Bentsur, Chairman and CEO, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
The company reported clinical data for NXP900, demonstrated robust pharmacodynamic response, and announced a $15.5M financing extending cash runway into Q1 2027.
Highlights from the company's research on NXP900, including its pharmacodynamic responses and safety profile.